Efficacy and six-month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded dose Program (WSEDP)

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 8, Issue 3, 1998, Pages 135-143

  Ose, L ^a   Kastelein, J J P ^b   Scott, R ^c   Stein, E A ^d   Campodonico, S ^e   Escobar, I D ^f   Tate, A C ^g   Corsetti, L ^h   Shahane, A ⁱ   Mitchel, Y B ^g   Mercuri, M ^g  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d Pharmaceutical Product Development   (United States)

^e Clínica Vesalio   (Peru)

^f Associacion Colombiana de Diabetes ^*  (Colombia)

^g MERCK RESEARCH LABORATORIES   (United States)

^h Clinical Research   (United States)

ⁱ BARDS   (United States)

Author keywords

Controlled clinical trial; High density lipoprotein; Hypercholesterolaemia; Low density lipoprotein cholesterol; Simvastatin; Triglycerides

Indexed keywords

EID: 0001127791     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269:3015-3023
2. Vartiainen E, Puska P, Pekkanen J, Tuomiletho J, Jousilahti P (1994) Changes in risk factors explain changes in mortality from ischemic heart disease in Finland. Br Med J 309: 23-27
3. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. (1984) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374
4. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344: 1383-1389
5. Pedersen TR, Berg K, Cook TJ et al (1996) Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156: 2085-2092
6. Davidson MH, Stein EA, Dujovne CA et al (1997) The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 79:38-42
7. Krauss RM, Deckelbaum RJ, Ernst N et al (1996) Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 94:1795-1800
8. Myers G, Cooper G, Winn C, Smith S (1989) The Centers for Disease Control National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 9:105-135
9. Steiner P, Freidel J, Bremner W, Stein E (1981) Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem 19: 850
10. Warnick G, Albers J (1978) A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19:65-76
11. Santer S, Santen R, Kulin H, Demers L (1981) A model for validation of radioimmunoassay kit reagents: measurement of follitropin and lutropin in blood and urine. Clin Chem 27:1892-1895
12. Kubasik N, Hallaver G, Brodows R (1984) Evaluation of direct solid phase radioimmunoassay for progesterone, useful for monitoring luteal function. Clin Chem 30:284-286
13. Tdx System Operator's Manual, Abbot Diagnostics, Abbot Park, IL; 1993
14. Newton WT, McGuigan JE, Jaffe BM (1970) Radioimmunoassay of peptides lacking tyrosine. J Lab Clin Med 75:886-892
15. Tolman KG (1980) Nitrofurantoin and chronic active hepatitis. Ann Intern Med 92: 119-120
16. Bradford RH, Shear CL, Chremos AN et al (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151: 43-49
17. Jones PH, Farmer JA, Cressman MD et al (1991) Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 14:146-151
18. Nawrocki JW, Weiss SR, Davidson MH et al (1995) Reduction of LDL-cholesterol by 25% to 60% in patients with hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678-682
19. Scandinavian Simvastatin Survival Study Group (1995) Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345:1274-1275
20. Pedersen TR, Olsson AG, Fogermen O et al (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453-1460
21. Stein AE, Lane M, Laskarzewski P (1998) Comparison of statins in hypertriglyceridemia. Am J Cardiol 81: 66B-69B
22. Arad Y, Ramakrishnan R, Ginsberg HN (1992) Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41: 487-498
23. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM (1996) Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128-133
24. Shear CL, Franklin FA, Stinnett S et al (1992) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 85: 1293-1303
25. Stein EA, Davidson MH, Dujovne CA et al (1996) Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardovasc Pharmacol Ther 1: 107-116
26. Bruckert E, De Gennes JL, Malbecq W, Baigts F (1995) Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol 18: 621-629
27. Pedersen TR, Tobert JA (1996) Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. Drug Saf 14: 11-24
28. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (1995) Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15: 678-682
29. Mol MJ, Stalenhoef AF, Stuyt PM, Hermus AR, Demacker PNM, Van T Laar A (1989) Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol 31: 679-689
30. Candrina R, Balestrieri G, Salvi A, Di Stefano O, Spandrio S, Giustina G (1990) Cortisol secretion in patients on simvastatin. Lancet 335: 53, Letter